A biotech startup has dosed the first human patient with a drug aimed at reversing age-related sight loss. The treatment is part of a broader effort to reverse cellular aging, with some outlets reporting that the therapy is designed to make old cells act young again. However, the timing of the human test is unclear, with one report stating it has begun and another saying it will start shortly.